List of Dhivy drug patents

Dhivy is owned by Avion Pharms.

Dhivy contains Carbidopa; Levodopa.

Dhivy has a total of 1 drug patent out of which 0 drug patents have expired.

Dhivy was authorised for market use on 12 November, 2021.

Dhivy is available in tablet;oral dosage forms.

Dhivy can be used as treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg.

The generics of Dhivy are possible to be released after 28 March, 2039.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033521 AVION PHARMS Levodopa fractionated dose composition and use
Mar, 2039

(16 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Market Authorisation Date: 12 November, 2021

Treatment: Treatment of parkinson's disease; Method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; Method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg

Dosage: TABLET;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic